Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

hair thinning
progression of prostate cancer
adenopathy
docetaxel
adenocarcinoma
  • 0 views
  • 16 Feb, 2024
  • 18 locations
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical study in adult patients with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable …

unconjugated hyperbilirubinemia
copanlisib
primary tumor
CHEK1
BARD1
  • 0 views
  • 16 Feb, 2024
  • 1 location
Metastasis-directed Therapy in Castration-refractory Prostate Cancer

The aim is to define the postponement of next line systemic treatment (NEST), by the use of metastasis-directed therapy in patients with oligoprogressive castration-refractory prostate cancer. This will be defined by the NEST-free survival. Furthermore the investigators will use 18F PSMA PET-CT as investigational imaging, to assess the predictive value …

pet/ct
primary tumor
adenocarcinoma
docetaxel
metastasectomy
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

targeted therapy
castration-resistant prostate cancer
solid neoplasm
adenocarcinoma
gonadotropin releasing hormone
  • 0 views
  • 16 Feb, 2024
  • 7 locations
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

progressive disease
bone scan
bone lesion
castration-resistant prostate cancer
metastasis
  • 0 views
  • 05 Aug, 2020
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

bilateral orchiectomy
gonadotropin
progressive disease
ejection fraction
gonadotropin releasing hormone
  • 0 views
  • 16 Feb, 2024
  • 4 locations
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

rimiducid
cancer
metastatic cancer
metastatic hormone refractory prostate cancer
castration-resistant prostate cancer
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

gonadotropin
androgens
adenocarcinoma
gonadotropin releasing hormone
antiandrogen therapy
  • 0 views
  • 05 Aug, 2020
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

antiandrogens
cancer
testosterone
docetaxel
combined modality therapy
  • 0 views
  • 16 Feb, 2024
  • 22 locations
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

This phase II study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death.

stage iv prostate cancer ajcc v8
carcinoma
biospecimen collection
prostate-specific antigen
metastasis
  • 0 views
  • 16 Feb, 2024
  • 1 location